PCSK9 is a protein your liver makes that controls how much cholesterol stays in your bloodstream. Its full name, proprotein convertase subtilisin/kexin type 9, rarely comes up outside a lab, but the protein itself has become one of the most important targets in heart disease prevention. Understanding what PCSK9 does explains why some people have naturally low cholesterol their entire lives, and why a newer class of medications can dramatically lower LDL (“bad”) cholesterol when statins aren’t enough.
How PCSK9 Raises Cholesterol
Your liver removes LDL cholesterol from the blood using surface proteins called LDL receptors. Think of these receptors as docking stations: they grab LDL particles, pull them inside the liver cell for disposal, then return to the cell surface to grab more. This recycling process is what keeps your LDL levels in check.
PCSK9 disrupts that recycling. When PCSK9 binds to an LDL receptor, both get pulled inside the cell together, just like normal. But normally, the receptor would release its cargo in the cell’s acidic interior and travel back to the surface. PCSK9 prevents that release. The acidic environment actually tightens PCSK9’s grip on the receptor, locking the two together. The receptor can’t change shape the way it needs to in order to detach and recycle. Instead, both the receptor and PCSK9 are routed to the cell’s waste-processing compartment and destroyed.
The result: fewer LDL receptors on the liver’s surface, fewer LDL particles pulled from the blood, and higher cholesterol levels. The more PCSK9 your body produces, the fewer receptors survive, and the higher your LDL climbs.
What Natural Mutations Revealed
Scientists first understood PCSK9’s importance by studying people born with unusual versions of the gene. Some families carry mutations that make PCSK9 overactive, leading to extremely high cholesterol and early heart attacks. But the more exciting discovery went the other direction: some people carry “loss-of-function” mutations that reduce PCSK9 activity from birth.
A pooled analysis across nine studies found that African Americans with these mutations had LDL cholesterol roughly 35 mg/dL lower than average throughout their lives, while white participants with a different loss-of-function variant had LDL about 13 mg/dL lower. Those differences translated directly into heart protection. African Americans with the larger LDL reduction had approximately 49% lower odds of coronary heart disease. The white participants, with a smaller but still lifelong LDL reduction, had about 18% lower odds. The key insight: even modest LDL reductions, sustained over decades, compound into substantial protection against heart disease.
How PCSK9 Inhibitors Work
Medications that block PCSK9 take two fundamentally different approaches. Monoclonal antibodies (evolocumab and alirocumab) work outside the cell. They’re engineered proteins that circulate in the bloodstream and physically grab PCSK9 before it can attach to LDL receptors. With PCSK9 neutralized, more receptors survive and keep clearing LDL from the blood.
The newer approach uses a technology called small interfering RNA (inclisiran). Instead of blocking PCSK9 after it’s made, inclisiran enters the liver cell and shuts down production at the source. It binds to the cell’s protein-building machinery for PCSK9, preventing the gene’s instructions from being translated into the actual protein. Fewer PCSK9 molecules get made in the first place.
Both approaches preserve more LDL receptors on liver cells, but they differ in practical ways that matter to patients.
How Much They Lower LDL
PCSK9 inhibitors are among the most potent cholesterol-lowering medications available. In patients with familial hypercholesterolemia (an inherited condition causing very high cholesterol), studies show LDL reductions ranging from about 35% to 60% when added to existing statin therapy. In one trial, evolocumab reduced LDL by an average of 53.6% after 48 weeks. Alirocumab at higher doses achieved reductions of around 49% to 55%. Even in patients with the most severe inherited form of high cholesterol, who are notoriously difficult to treat, LDL dropped by about 31% compared to placebo.
These reductions translate into fewer heart attacks and strokes. In a large trial of alirocumab in patients who had recently experienced a serious cardiac event, the medication reduced major adverse cardiovascular events with a hazard ratio of 0.88, meaning roughly a 12% reduction in heart attacks, strokes, and related deaths compared to placebo.
Injection Schedules
All currently approved PCSK9 therapies are given by injection under the skin, but the frequency varies considerably. Evolocumab and alirocumab require injections every two weeks (or monthly for some evolocumab dosing). Many patients self-inject at home using a prefilled pen, similar to insulin.
Inclisiran offers a much lighter schedule: an initial injection, a second at three months, then one injection every six months after that. Those twice-yearly doses are typically given in a doctor’s office, which can simplify adherence for people who struggle with frequent self-injection.
Side Effects and Safety
PCSK9 inhibitors have a generally favorable safety profile. The most common side effects in both clinical trials and real-world use are mild: flu-like symptoms, upper respiratory symptoms, muscle aches, and reactions at the injection site such as redness, bruising, or soreness. In one hospital registry of 164 patients, about 42% reported at least one side effect at their first follow-up, with flu-like illness (28%) and nasal congestion or sore throat (16%) being the most frequent. Injection-site reactions affected about a third of patients in that group but did not cause anyone to stop treatment.
Muscle pain is worth noting because many patients prescribed PCSK9 inhibitors have already had trouble tolerating statins due to muscle symptoms. In real-world adverse event databases, myalgia was consistently among the top reported side effects (8% to 13% depending on the data source) and was the most common reason patients discontinued treatment in one pharmacovigilance database. Only about 7% of patients in the hospital registry stopped their medication overall.
One area of ongoing attention is brain health. Two meta-analyses found a small but statistically significant increase in neurocognitive side effects (such as difficulty concentrating or memory complaints) among PCSK9 inhibitor users compared to controls. Whether this reflects genuinely low LDL levels, the medication itself, or reporting bias remains unclear, but dedicated cognitive studies so far have not confirmed lasting harm.
Who Is Prescribed PCSK9 Therapy
Current guidelines from the American College of Cardiology reserve PCSK9 inhibitors for patients who need additional LDL lowering beyond what statins and other first-line treatments can achieve. For patients who have had a recent heart attack or other acute coronary event and are already on the highest statin dose they can tolerate, adding a PCSK9 inhibitor (or inclisiran, or another nonstatin agent) is recommended if LDL remains at or above 70 mg/dL. Guidelines also call it reasonable to add these therapies when LDL sits between 55 and 69 mg/dL in the same high-risk population.
In practice, most people taking PCSK9 inhibitors fall into a few groups: those with familial hypercholesterolemia whose LDL stays dangerously high despite statins, those who have already had a cardiovascular event and need aggressive LDL reduction, and those who cannot tolerate statins at effective doses.
An Oral Option on the Horizon
One of the biggest barriers to PCSK9 therapy has been the requirement for injections. That may change. An oral PCSK9 inhibitor called enlicitide decanoate (developed as MK-0616) is currently in phase 3 clinical trials. Rather than an antibody or RNA-based therapy, it uses a small molecule designed to block PCSK9 in pill form. Early trial results in patients with familial hypercholesterolemia were published in JAMA in early 2025, and several additional phase 3 studies are underway evaluating its effect on LDL levels over 24 weeks and beyond. If approved, a daily pill targeting PCSK9 could make this class of therapy accessible to a much broader group of patients.